Antibodies for the prevention or the treatment of bleeding episodes
The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13-mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).
1. A method for treating bleeding episodes in a patient in need thereof, wherein the bleeding episodes are characterized by increased von Willebrand factor (VWF) proteolysis, comprising administering to the patient a therapeutically effective amount of
a monoclonal antibody having a heavy chain variable region and a light chain variable region, wherein the monoclonal antibody specifically binds to a peptide of SEQ ID NO: 1 derived from the D4 domain of human VWF, which competes for binding to VWF D4 domain with A Disintegrin And Metalloprotease with ThromboSpondin domains-13 (ADAMTS13) and inhibits between 50 and 80% of ADAMTS13-mediated degradation of high molecular weight (HMW)-multimers of VWF, wherein
the heavy chain variable region comprises
i) an amino acid sequence as set forth in SEQ ID NO:2,
or
ii) an H-CDR1, having an amino acid sequence as set forth in SEQ ID NO:3; an H-CDR2, having an amino acid sequence as set forth in SEQ ID NO:4; and an H-CDR3, having an amino acid sequence as set forth in SEQ ID NO:5;
and
the light chain variable region comprises
iii) an amino acid sequence as set forth in SEQ ID NO:6,
or
iv) a L-CDR1, having an amino acid sequence as set forth in SEQ ID NO:7; a L-CDR2, having an amino acid sequence as set forth in SEQ ID NO:8; and a L-CDR3, having an amino acid sequence as set forth in SEQ ID NO:9;
or a fragment thereof, wherein the fragment thereof comprises each of the H-CDR1, the H-CDR2, the H-CDR-3, the L-CDR1, the L-CDR-2, and the L-CDR3.
2. The method according to claim 1 , wherein the bleeding episodes are gastrointestinal (GI) bleedings.
3. The method according to claim 1 , wherein the patient in need thereof is selected from the group consisting of a patient carrying a circulatory assist device, a patient suffering from aortic stenosis, a patient with hereditary von Willebrand disease type 2A and a patient having extracorporeal membrane oxygenation support.